Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancerFeng Wang(Albert Einstein College of Medicine), Balázs Halmos(University Hospitals of Cleveland)Translational Cancer ResearchOctober 1, 201910.21037/tcr.2019.09.61Cited by 28SaveCiteExport RISWatch citationsRelated PapersTranscriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling|Cancer Research|2006|149Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1|PLoS ONE|2014|40Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways|Cancers|2023|15